The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

Me, which helped popularize ancestry tracing through genetic testing, filed for bankruptcy protection and will seek a sale.

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

As thousands of Chinese families take DNA tests, the results are upending what adoptees abroad thought they knew about their ...

Regeneron Pharmaceuticals has agreed to buy 23andMe for $256 million and plans to continue consumer DNA testing services ...

Regeneron to acquire nearly all of 23andMe’s assets for $256M, marking a new chapter for the direct-to-consumer genetic testing pioneer.

23andMe's stock, which once traded for more than $300 a share, fell to 79 cents before the start of trade Monday. In January, 23andMe reported a third-quarter net loss of $26.8 million on revenue ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

The once-popular genetic testing company will be acquired by Regeneron after filing for bankruptcy, but the questions about ...

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug discovery.